P&G Health's Q4 profit jumps 55% on strong pharma demand
Annual net profit reached ₹327 crore. The board has declared a final dividend of ₹45 per share, taking the full-year payout to ₹205.
— 2 earlier stories on Procter & Gamble Health Ltd. →What's new
- Q4 revenue rose 19% year-on-year to ₹370 crore; net profit jumped 55% to ₹95 crore.
- Full-year revenue was ₹1,408 crore with net profit of ₹327 crore.
- Board recommended a final dividend of ₹45 per share, making the total FY26 dividend ₹205 per share.
Why this matters
P&G Health delivered a clean beat in the final quarter. The 55% profit jump on 19% sales growth points to improving profitability in its pharma portfolio. The unmodified audit opinion and the total dividend of ₹205 per share confirm a year of strong, unencumbered cash generation.
What we're watching
- Whether the 55% Q4 profit growth is sustainable into FY27 or driven by one-off demand.
- Management commentary on pricing and input costs in the concall.
- Any change in dividend payout ratio from the elevated FY26 level.
The full read
P&G Health closed a strong fiscal year. Q4 revenue hit ₹370 crore (+19% YoY), but the real story was profit, which jumped 55% to ₹94.60 crore. That spread between sales and profit growth points to improving margins in the pharma segment. For the full year, revenue reached ₹1,408 crore with net profit of ₹327 crore. The board has now declared a final dividend of ₹45 per share, bringing the total FY26 payout to ₹205 per share after earlier interim and special dividends. The audit came back clean, with an unmodified opinion. The results were largely expected, but they confirm that P&G Health is generating strong, growing cash flow for its owners.
Questions answered
- What drove the 55% jump in Q4 net profit?
- The results cited strong demand for the company's pharmaceutical products. The 55% profit growth on 19% revenue growth suggests improving profitability in the quarter.
- How much will shareholders receive in dividends for FY26?
- Shareholders will receive a total of ₹205 per share for the year. This includes the ₹45 final dividend approved in this board meeting, plus earlier interim and special dividends.
- Were there any red flags in the audit?
- No. The company's auditors issued an unmodified opinion on the financial statements, meaning there were no qualifications or emphasis-of-matter paragraphs in the report.
- Is this quarter's performance a departure from the past?
- The filing describes the results as consistent with the company's track record and notes they were widely anticipated. The strong Q4 may represent an acceleration rather than a one-off spike.
Procter & Gamble Health Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on PGHL →- 26 May 2026 · 4:57 PM IST P&G Health's Q4 profit jumps 55% on strong pharma demand
- 18d ago P&G Health's FY26 sales up 16%, profit up 30%; innovation and distribution gain
- 41d ago Procter & Gamble Health posts 30% profit growth for FY26